Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Supernus Pharmaceuticals Inc’s stock clocked out at $44.7, down -1.95% from its previous closing price of $45.59. In other words, the price has decreased by -$1.95 from its previous closing price. On the day, 0.56 million shares were traded. SUPN stock price reached its highest trading level at $45.58 during the session, while it also had its lowest trading level at $44.655.
Ratios:
To gain a deeper understanding of SUPN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.12 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 36.23. For the most recent quarter (mrq), Quick Ratio is recorded 1.56 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On July 30, 2025, Cantor Fitzgerald Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $42. Cantor Fitzgerald Downgraded its Overweight to Neutral on February 19, 2025, whereas the target price for the stock was revised from $57 to $36.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 09 ’25 when Khattar Jack A. sold 59,900 shares for $50.57 per share. The transaction valued at 3,029,336 led to the insider holds 1,206,578 shares of the business.
NEWHALL CHARLES W III sold 25,000 shares of SUPN for $1,269,234 on Oct 09 ’25. The Director now owns 104,644 shares after completing the transaction at $50.77 per share. On Oct 09 ’25, another insider, JACK A. KHATTAR, who serves as the Director of the company, bought 59,900 shares for $48.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SUPN now has a Market Capitalization of 2563069184 and an Enterprise Value of 2324120832. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.76 while its Price-to-Book (P/B) ratio in mrq is 2.43. Its current Enterprise Value per Revenue stands at 3.41 whereas that against EBITDA is 19.54.
Stock Price History:
The Beta on a monthly basis for SUPN is 0.72, which has changed by 0.23116398 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, SUPN has reached a high of $57.65, while it has fallen to a 52-week low of $29.16. The 50-Day Moving Average of the stock is -7.94%, while the 200-Day Moving Average is calculated to be 16.45%.
Shares Statistics:
It appears that SUPN traded 847.83K shares on average per day over the past three months and 739630 shares per day over the past ten days. A total of 57.12M shares are outstanding, with a floating share count of 54.43M. Insiders hold about 5.07% of the company’s shares, while institutions hold 101.49% stake in the company. Shares short for SUPN as of 1763078400 were 5202679 with a Short Ratio of 6.14, compared to 1760486400 on 4954765. Therefore, it implies a Short% of Shares Outstanding of 5202679 and a Short% of Float of 12.810000999999998.
Earnings Estimates
At present, 3.0 analysts are actively evaluating the performance of Supernus Pharmaceuticals Inc (SUPN) in the stock market.The consensus estimate for the next quarter is $0.44, with high estimates of $0.47 and low estimates of $0.42.
Analysts are recommending an EPS of between $5.95 and $2.63 for the fiscal current year, implying an average EPS of $3.81. EPS for the following year is $4.25, with 3.0 analysts recommending between $6.04 and $3.25.
Revenue Estimates
In. The current quarter, 6 analysts expect revenue to total $195.48M. It ranges from a high estimate of $202.7M to a low estimate of $184.8M. As of. The current estimate, Supernus Pharmaceuticals Inc’s year-ago sales were $174.16MFor the next quarter, 6 analysts are estimating revenue of $192.18M. There is a high estimate of $203.7M for the next quarter, whereas the lowest estimate is $182.5M.
A total of 6 analysts have provided revenue estimates for SUPN’s current fiscal year. The highest revenue estimate was $710M, while the lowest revenue estimate was $692.2M, resulting in an average revenue estimate of $702.84M. In the same quarter a year ago, actual revenue was $661.82MBased on 6 analysts’ estimates, the company’s revenue will be $867.02M in the next fiscal year. The high estimate is $902.5M and the low estimate is $824.1M.
